Mario V.
- Country
- Italy
- Department
- 9220:U.O. Dermatologia
Research Overview
- Phase 3 Extension Study of Long-Term Safety and Efficacy of Remibrutinib in Adults With Moderate to Severe Hidradenitis Suppurativa
- Long-Term Safety and Efficacy Evaluation of Povorcitinib in Moderate to Severe Hidradenitis Suppurativa: A Phase 3 Double-Blind Study
- Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
Data & Insights
Has run more than one trial at 78 of 157 partner sites.
Specializations
Dermatological Research
This investigator specializes in studying innovative treatments for Hidradenitis Suppurativa, a chronic inflammatory skin condition. Their research focuses on evaluating therapeutic approaches using povorcitinib for managing this challenging dermatological disorder.
- Chronic Inflammatory Skin Conditions
- Long-term Treatment Outcomes
- Therapeutic Safety Assessment
The investigator's work centers on understanding extended treatment outcomes in dermatological conditions.
Clinical Safety Studies
The investigator conducts comprehensive research into the long-term safety profiles of dermatological treatments, particularly focusing on selective therapeutic agents in chronic skin conditions.
- Drug Safety Evaluation
- Extended Treatment Monitoring
- Patient Safety Outcomes
Their expertise includes monitoring extended treatment periods to establish comprehensive safety profiles.
Therapeutic Innovation
The investigator explores selective treatment approaches in dermatology, focusing on novel therapeutic agents for chronic inflammatory conditions.
- Novel Treatment Development
- Therapeutic Efficacy
- Treatment Optimization
Their research encompasses innovative therapeutic strategies for managing chronic skin disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.